Sunday 11 October 2026
Export all BMY data to Excel Powerpack
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
59.12
0.46
−0.77%
Follow BMY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 46.63% | 38.75% | 40.43% | 33.74% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
7 | 7 | 8 | 7 | |
| 10.18% | 8.13% | 7.72% | 6.34% | ||
ROIC |
13.69% | 11.09% | 11.01% | 9.83% | |
Return on Tangible Assets |
52.41% | 46.31% | 52.19% | 40.69% | |
Average Days of Receivables |
78.31 | 70.53 | 86.44 | 86.79 | |
Free Cash Flow per Share |
5.60 | 5.84 | 6.32 | 7.52 | |
Free Cash Flow |
11,440.00 | 11,908.00 | 12,845.00 | 15,302.00 | |
Capital Expenditures |
(1,342.00) | (1,398.00) | (1,311.00) | (1,319.00) | |
| Other line items | |||||
Cash ROIC |
14.95% | 15.87% | 17.29% | 18.20% | |
Accounts Receivable Turnover |
4.48 | 4.81 | 4.35 | 4.28 | |
Accounts Payable Turnover |
3.06 | 3.48 | 3.88 | 3.78 | |
Inventory Turnover |
5.36 | 5.28 | 5.31 | 4.81 | |
Average Days of Payables |
103.40 | 107.89 | 93.63 | 106.82 | |
Days of Inventory on Hand |
68.06 | 70.23 | 70.45 | 68.71 | |
Tax Rate |
(0.22) | (0.24) | (0.24) | (0.25) | |
Research and Development Expense of Revenue |
21.80% | 21.33% | 20.65% | 21.98% | |
Selling, General and Administrative Expense of Revenue |
15.07% | 15.06% | 15.08% | 15.04% | |
Share Based Compensation of Revenue |
1.12% | 1.14% | 1.15% | 1.12% | |
Operating CF/Net income |
1.38 | 1.83 | 2.01 | 2.75 | |
Depreciation/Fixed assets |
0.41 | 0.47 | 0.53 | 0.67 | |
Capex/Depreciation |
(0.42) | (0.39) | (0.33) | (0.27) | |
Revenue per Share |
24.09 | 23.79 | 23.69 | 23.59 | |
Operating CF per Share |
6.26 | 6.53 | 6.96 | 8.16 | |
Capex per Share |
(0.66) | (0.69) | (0.64) | (0.65) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.03 |
Columns are period end dates